Emerging niche business cluster eyes challenge
Manx-based BioMed Pharmacovigilance firm Panacea says there are risks posed by Brexit to the sector on the Isle of Man.
The company gathers, monitors and analyses medicines as they hit the market, and has been waxing lyrical about the Island's BioMed environment in the UK press recently.
It's been working within what it describes as the 'burgeoning' Manx cluster of specialist companies, and with the Isle of Man Government, to attract more enterprises to relocate here.
In the post-Brexit landscape, the firm sees both risks and opportunities.
Panacea business development manager Sam Tipper gave a corporate health check as Prime Minister Theresa May prepares to trigger the UK's EU exit:
Businesses invited to meeting to discuss pending Minimum Wage rise
Chamber urges voters to back candidates who will make Island a 'competitive international jurisdiction'
Post Office to raise letter prices and bring in stamp expiry dates
Sight Matters highlight the importance of Will Writing Month
